Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
Private price negotiation is a hallmark of the US health care system – banning rebates does not make that any less true.
As drug prices climb, is it time to ask whether the landmark technology transfer law is a fair deal for US taxpayers?
Regulatory intervention having limited impact on fostering innovation.
Novartis is the latest big pharma company to pledge not to increase drug prices. But does this signal a shift in the industry?
Will US right-to-try legislation be a means of giving hope to terminally ill patients, or drug another way for drug regulatory standards to fall?
A recent US push to end drug rebates might improve transparency, but will do nothing to address the root cause of rising drug costs.
Competitive bidding, an attempt to bring down Medicare costs, might lead to higher out-of-pocket costs for patients.
The US government is trying to change the way Medicare reimburses doctors for office-administered drugs – but whether it will succeed is another story.